Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2001-3-6
pubmed:abstractText
The aim of our study was to evaluate whether the prophylactic use of ibuprofen would reduce the incidence of significant patent ductus arteriosus (PDA) and to confirm the effectiveness of ibuprofen as rescue treatment in closing PDA. Eighty preterm infants with gestational age less than 34 wk with infant respiratory distress syndrome (iRDS) were randomized to receive intravenous ibuprofen lysine (10 mg/kg, followed by 5 mg/kg after 24 and 48 h) either within 24 h of life (group A) or after echocardiographic diagnosis of PDA (group B). To evaluate the severity of RDS in each patient, we calculated the initial and highest values of Oxygenation Index (O.I. = mean airway pressure x FiO2 x 100/PaO2) and Ventilatory Index (V.I. = O.I. x mechanical respiratory rate). Other studied variables were ventilatory support, renal function, biochemical and haematological profiles, frequency of bronchopulmonary dysplasia (BPD), intraventricular haemorrhage (IVH), necrotizing enterocolitis (NEC) and retinopathy of prematurity (ROP). On the 3rd day of life, 8% (3/40) of patients of group A and 53% of patients (21/40) of group B (p < 0.0001) developed a significant PDA. Between patients of group B who presented PDA at 3 d of life 90% (19/21) had a closure of ductus arteriosus after ibuprofen treatment. Initial and highest values of O.I. and V.I. were similar in both groups A and B. No significant differences between the groups were observed in regard to respiratory support, renal function and frequency of BPD, IVH, NEC and ROP. Ibuprofen was not associated with adverse effects. Conclusion: Prophylactic treatment with ibuprofen reduces PDA occurrence in preterm infants with iRDS at 3 d of life in comparison with rescue treatment, but both modes are effective in closing the ductus without significant adverse effects.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0803-5253
pubmed:author
pubmed:issnType
Print
pubmed:volume
89
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1369-74
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11106052-Age Factors, pubmed-meshheading:11106052-Anti-Inflammatory Agents, Non-Steroidal, pubmed-meshheading:11106052-Apgar Score, pubmed-meshheading:11106052-Birth Weight, pubmed-meshheading:11106052-Cyclooxygenase Inhibitors, pubmed-meshheading:11106052-Data Interpretation, Statistical, pubmed-meshheading:11106052-Ductus Arteriosus, Patent, pubmed-meshheading:11106052-Echocardiography, Doppler, pubmed-meshheading:11106052-Female, pubmed-meshheading:11106052-Gestational Age, pubmed-meshheading:11106052-Humans, pubmed-meshheading:11106052-Ibuprofen, pubmed-meshheading:11106052-Incidence, pubmed-meshheading:11106052-Infant, Newborn, pubmed-meshheading:11106052-Infant, Premature, pubmed-meshheading:11106052-Injections, Intravenous, pubmed-meshheading:11106052-Male, pubmed-meshheading:11106052-Respiration, Artificial, pubmed-meshheading:11106052-Respiratory Distress Syndrome, Newborn, pubmed-meshheading:11106052-Time Factors
pubmed:year
2000
pubmed:articleTitle
Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants.
pubmed:affiliation
Division of Neonatology, Careggi University Hospital of Florence, Italy. cdani@.unifi.it
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial